Insider Selling: GeneDx (NASDAQ:WGS) CEO Sells $155,382.00 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 1,653 shares of the business’s stock in a transaction that occurred on Thursday, January 29th. The stock was sold at an average price of $94.00, for a total value of $155,382.00. Following the transaction, the chief executive officer directly owned 16,458 shares in the company, valued at $1,547,052. This trade represents a 9.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Katherine Stueland also recently made the following trade(s):

• On Tuesday, December 16th, Katherine Stueland sold 10,857 shares of GeneDx stock. The shares were sold at an average price of $143.89, for a total transaction of $1,562,213.73.
• On Tuesday, December 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The stock was sold at an average price of $159.28, for a total transaction of $579,619.92.

GeneDx Stock Performance

Shares of WGS stock opened at $85.35 on Thursday. The company has a fifty day moving average price of $129.42 and a two-hundred day moving average price of $124.86. GeneDx Holdings Corp. has a one year low of $55.17 and a one year high of $170.87. The stock has a market cap of $2.47 billion, a P/E ratio of 948.33 and a beta of 2.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Analyst sentiment remains constructive — several firms maintain Buy/Upgraded ratings and the consensus is a “Moderate Buy,” which supports medium‑term upside. Analyst Consensus
• Neutral Sentiment: Company scheduled to report Q4 2025 results on Feb 23, 2026 — a clear near‑term catalyst that can either amplify a rebound or deepen the decline depending on results and guidance. Q4 2025 Release Date
• Negative Sentiment: Clustered insider selling by senior executives: COO Bryan Dechairo sold 3,413 shares (~$339.7k) and CEO Katherine Stueland sold 1,653 shares; the CFO also sold 317 shares — these C‑suite sales can signal reduced near‑term insider conviction and weigh on investor sentiment. COO Sale CEO Sale CFO Sale
• Negative Sentiment: Technical and flow factors look unfavorable: shares are trading well below recent 50‑day and 200‑day averages and turnover is elevated versus normal volume — these conditions often trigger momentum selling and increase volatility. Price & Technicals

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in WGS. Jones Financial Companies Lllp boosted its position in shares of GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after acquiring an additional 186 shares during the period. Quarry LP boosted its holdings in GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after purchasing an additional 209 shares during the period. Gordian Capital Singapore Pte Ltd bought a new stake in GeneDx in the 3rd quarter valued at about $65,000. AlphaQuest LLC grew its position in shares of GeneDx by 351.5% during the 2nd quarter. AlphaQuest LLC now owns 763 shares of the company’s stock worth $70,000 after purchasing an additional 594 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of GeneDx by 479.0% during the second quarter. Tower Research Capital LLC TRC now owns 1,818 shares of the company’s stock worth $168,000 after purchasing an additional 1,504 shares during the period. Institutional investors own 61.72% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on WGS shares. Canaccord Genuity Group raised their price objective on GeneDx from $160.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a report on Wednesday, January 21st. Guggenheim reaffirmed a “buy” rating and set a $170.00 price objective (up from $115.00) on shares of GeneDx in a research report on Wednesday, October 29th. BTIG Research increased their price objective on shares of GeneDx from $165.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Finally, Wall Street Zen upgraded shares of GeneDx from a “hold” rating to a “buy” rating in a research note on Saturday, January 31st. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $138.13.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.